Revolution Medicines commercialization chief reports sale of $431,946.90 in common shares

RVMD•2026-10-28

Revolution Medicines Chief Global Commercialization Officer Anthony Mancini sold 2,310 common shares at $186.99 each on October 26, 2026, and exercised options to buy 2,310 shares at $33.62 each.

1. Mancini’s transactions

A Form 4 filed October 28, 2026, showed that Mancini’s direct common stock holdings totaled 39,765 shares after the transactions.

Sources

Revolution Medicines commercialization chief reports sale of $431,946.90 in common shares

Sec

Revolution Medicines commercialization chief reports sale of $431,946.90 in common shares

1. Mancini’s transactions

Related News

Origin Bancorp expects low-double-digit net interest income growth in 2026

Hilton publishes Q3 2026 earnings call transcript

Instacart shares rise as DoorDash takeover may reportedly be announced Thursday

Sources

Revolution Medicines commercialization chief reports sale of $431,946.90 in common shares

FedEx margins decline, shares fall despite bigger-than-expected quarterly profit

FirstEnergy Transmission enters amendment to $1 billion credit agreement